Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Uni-Bio Science Group Ltd. ( (HK:0690) ) has issued an announcement.
Uni-Bio Science Group Ltd. reported a 14.1% increase in revenue to approximately HK$553.0 million and a 16.8% rise in profit to HK$82.8 million for the year ended December 31, 2024, marking a historic high. The company launched Bogutai®, which exceeded sales expectations, and recommended a final dividend payment. The company also introduced a new medical aesthetics product and advanced its ophthalmology drug pipeline, reinforcing its commitment to innovation and cost control.
More about Uni-Bio Science Group Ltd.
Uni-Bio Science Group Ltd. is a leading biopharmaceutical company focused on developing innovative healthcare solutions. The company specializes in biopharmaceuticals and medical aesthetics products, with a market focus on sustainable and high-quality growth in the healthcare industry.
YTD Price Performance: 21.67%
Average Trading Volume: 8,929,199
Technical Sentiment Signal: Sell
Current Market Cap: HK$417M
Learn more about 0690 stock on TipRanks’ Stock Analysis page.